

Curriculum vitae

Patrick G. Clay, PharmD

Director, Dybedal Center for Clinical Research & Director, Clinical Research
 Associate Professor of Medicine, College of Osteopathic Medicine
 Kansas City University of Medicine and Biosciences
 1750 Independence Avenue
 Kansas City, Missouri 64116
 Website: www.kcumb.edu/crc.asp
 Email: pclay@kcumb.edu;
 Office: (816) 654-7652
 Fax: (816) 654-7651
 Mobile: (816) 536-0974

Education and Post-Graduate Pharmacy Training

1988 – 1993 Bachelor of Science in Pharmacy, University of Louisiana at Monroe College of Pharmacy
 6/94 – 5/96 Doctor of Pharmacy, University of Oklahoma Health Sciences Center College of Pharmacy (OUHSC-COP)
 7/96 – 7/97 Specialty Residency in Infectious Diseases, University of Oklahoma Health Sciences Center Colleges of Pharmacy and Medicine (OUHSC-COP/M)
 7/97 – 7/99 Fellowship in Infectious Diseases, OUHSC-COP/M
 8/00 – 5/02 Business Information Technology coursework (non-degree seeking), UMKC School of Information Technology

Licensure

1994 - 1999 Louisiana (#15612) and Oklahoma (#11650)
 2000 – ONG Louisiana (#15612) and Missouri (#2001005462)

Certifications / Awards

2006 – ONG Certified Clinical Trial Administrator, Society of Research Administrators
 2007 – ONG Certification for Clinical Trial Investigators, Association of Clinical Research Professionals
 2007 Fellow, American College of Clinical Pharmacy

Appointments:

Academic

7/96 – 8/99 Instructor, Division of Pharmacy Practice, University of Oklahoma College of Pharmacy
 8/99 – 3/05 Assistant Professor, Division of Pharmacy Practice, University of Missouri-Kansas City
 4/05 – ONG Adjunct Associate Professor of Pharmacy Practice, Department of Pharmacy Practice, School of Pharmacy, University of Missouri – Kansas City
 4/05 – ONG Associate Professor of Medicine, College of Osteopathic Medicine, Kansas City University of Medicine and Biosciences
 6/09 – ONG Adjunct Associate Professor, St. Louis College of Pharmacy

Administrative

4/05 – ONG Director, Clinical Research, Kansas City University of Medicine and Biosciences

Clinical

9/99 – 3/05 Member, HIV Primary Care Team, Kansas City Free Health Clinic, Kansas City, Missouri
 9/99 – 11/03 Member, Program Team, Kansas City Free Health Clinic, Kansas City, Missouri
 11/99 – 4/00 Kansas City AIDS Research Consortium Protocol Review Committee, KCARC, Kansas City, Missouri
 7/00 – 7/01 Member, Kansas City Metropolitan Service Area Institutional Review Board Consortium, Kansas City, Missouri
 7/02 – 7/07 Midwest AIDS Education and Training Consortium; Pharmacists' Training Program Advisor, Kansas City, Missouri
 5/07 – 9/08 Member, Clinical Research Advisory Board, Kansas City Area Life Sciences Initiative, Kansas City, Missouri
 2/11 – ONG Science Officer, American Pharmacists Association, Washington, DC

Research activities

Original Research

1. **Clay PG***, McRae MP, Laurent JP. Two phase 1 studies of KP-1461, a novel human immunodeficiency virus decay accelerator. (**in press**. Journal International Association of Physicians in AIDS Care, March 2011).
2. McRae MP, **Clay PG**, Anderson PL, Glaros AG. Pharmacokinetic and safety of once daily fosamprenavir plus atazanavir without ritonavir in HIV-negative subjects. *Pharmacotherapy* 2009;29:937-42.
3. **Clay PG**, Vaught ER, Glaros A, Mangum SA, Hansen D, Lindsey CC. Costs to physicians offices of providing medications to medically indigent patients via pharmaceutical manufacturer prescription assistance programs. *J Manag Care Pharmacy* 2007;13:506-14.
4. Campo RE, Narayanan S, **Clay PG**, DeHovitz J, Johnson D, Jordan W, Squires K, Sajjan S, Markson L. Factors Influencing the Acceptance of Changes in Antiretroviral Therapy among HIV-1 Infected Patients. *AIDS Patient Care and STDs* 2007;21:329-38.
5. Ortiz BI, Shields KM, Clauson KA, **Clay PG**. Complementary and Alternative Medicine Use Among Hispanics in the United States. *Ann Pharmacother* 2007;41:994-1004. PMID: 17504837.
6. **Clay PG**, Glaros AG, Clauson KA. Perceived Efficacy, Indications, and Information Sources for Medically Indigent Patients and Their Healthcare Providers Regarding Dietary Supplements. *Ann Pharmacother* 2006 Mar;40(3):427-32. DOI 10.1345/aph.1E497
7. **Clay PG***. Program savings associated with switching testosterone formulation from intramuscular injections to topical gel in HIV infected males. *Curr Med Res Opin*. 2004 Apr;20(4):461-8. DOI 10.1185/030079904125003241
8. **Clay PG***, Clauson KA, Glaros A. Complementary and alternative medicine use in a medically-indigent free health clinic. *Curr Ther Res* 2004 Nov-Dec;65(6):481-494. DOI 10.1016/j.curtheres.2005.01.005
9. **Clay PG***, Graham MR, Lindsey CC, Freeman CA, Lamp KA, Glaros A. Clinical efficacy, safety and cost savings of once-daily metronidazole plus ceftriaxone (MTZ/CTX) compared to ticarcillin/clavulanate (T/C) as empiric treatment of diabetic lower extremity infections. *Am J Geriatr Pharmacother* 2004 Sep; 2(3):181-9. DOI 10.1016/j.amjopharm.2004.09.006
10. **Clay PG***. Actual medication pill burden and dosing frequency in HIV-infected patients with undetectable viral loads. *J Int Assoc Physicians AIDS Care* 2004 Apr-Jun;3(2):49-55. DOI 10.1177/154510970400300203
11. **Clay PG***. Program savings associated with switching testosterone intramuscular injections to topical gel in HIV-infected males. *Curr Med Res Opin* 2004;20:461-8.

** denotes corresponding author status*

Multi-center, PhRMA sponsored clinical trials (Site Principal Investigator):

Completed (if available, trial publications can be found in publications section)

1. Gilead Sciences, GS-99-903: A Phase 3, Randomized, Double-blind, multi-center study of the treatment of antiretroviral-naive, HIV-1-infected patients comparing tenofovir administered in combination with lamivudine and efavirenz versus stavudine, lamivudine and efavirenz.
2. Merck and Co., Inc., Merck Practice Cooperative study surveying patients' attitudes regarding changing their antiretroviral therapy for any reason
3. GlaxoSmithKline, CNA30032: a retrospective, case-control study to investigate genetic polymorphisms in HIV-infected subjects who developed hypersensitivity following treatment with abacavir
4. Boehringer-Ingelheim Pharmaceuticals, Inc.; 1182.51: Double blind, randomized, dose optimization pharmacokinetic trial of three doses of tipranavir boosted with low dose ritonavir (TPV/RTV) in multiple antiretroviral drug-experienced subjects
5. Boehringer-Ingelheim Pharmaceuticals Inc., 1182.52: Double blind, randomized, dose optimization trial of three doses of tipranavir boosted with low dose ritonavir (TPV/RTV) in multiple antiretroviral drug-experienced subjects
6. Agouron Pharmaceuticals Inc., AG1343-1205: Genotype assisted initial nelfinavir study (GAIN)
7. Bristol-Myers Squibb, AI266-406 "VEST-QD: A Phase IV, Open-label, randomized, multi-center, study switching HIV-1 infected subjects with a viral load of <50 copies/mL on a first PI-based regimen to a efavirenz substitution regimen
8. Boehringer-Ingelheim Pharmaceuticals Inc., 1182.12: RESIST-1: Randomized, open-label, comparative safety and efficacy study of tipranavir boosted with low-dose ritonavir (TPV/RTV) versus genotypically-defined protease inhibitor/ritonavir (PI/RTV) in multiple antiretroviral drug-experienced patients
9. Boehringer-Ingelheim Pharmaceuticals Inc., 1182.17: A long – term, open-label, rollover trial assessing the safety and tolerability of combination TPV/RTV use in HIV-1 infected subjects.
10. Bristol-Myers Squibb Inc., A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy and safety of saxagliptin (BMS-477118) as monotherapy in subjects with type 2 diabetes who have inadequate glycemic control with diet and exercise. (BMS CV181011).
11. Koronis Pharmaceuticals, KP-1461-102: A Double-Blind, Placebo-Controlled, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of KP-1461 in HIV+ Adults who have Failed Two or More Highly Active Antiretroviral Regimens (HAART).
12. Gilead Sciences, Expanded Access Program for Tenofovir Disoproxil Fumarate (Tenofovir DF) in the Treatment of HIV-1 Infected Patients Who Have Limited Treatment Options

13. Serono Labs, A pilot multi-center, open-label study to determine the efficacy and safety of serostim in HIV patients with unintentional weight loss or BCM depletion on combination antiretroviral therapy with or without protease inhibitors
14. Pfizer, Inc., Voriconazole expanded access program
15. Roche Pharmaceuticals, Inc., Enfuvirtide (Fuzeon) expanded access protocol
16. Boehringer-Ingelheim Pharmaceuticals, Inc., Expanded access protocol for tipranavir in patients with little or no treatment options available
17. Bristol-Myers Squibb Inc., Atazanavir expanded access study for HIV infected persons with few treatment options remaining
18. Pfizer Inc., Efficacy and safety of inhaled human insulin (exubera) compared with subcutaneous human insulin in the therapy of adult subjects with type 1 or type 2 diabetes mellitus and chronic obstructive pulmonary disease: a one-year, multicenter, randomized, outpatient, open-label, parallel-group comparative trial. (A2171030).
19. Novartis Pharmaceuticals, A 25-week treatment, multicenter, randomized, double-blind, placebo-controlled, adaptive, seamless, parallel-group study to assess the efficacy, safety and tolerability of two doses of indacaterol (selected from 75, 150, 300 & 600 µg o.d.) in patients with chronic obstructive pulmonary disease using blinded formoterol (12 µg b.i.d.) and open label tiotropium (18 µg o.d.) as active controls (CQAB149B2335S)
20. Boehringer-Ingelheim Pharmaceuticals, Inc., 1100.1489: Steady State Bioavailability of 2 different Viramune Extended Release formulations compared to steady state 400 mg of Viramune® (200 mg BID), in HIV infected subjects, an open label, non randomized, multidose and multistage parallel group study. (ERVIR)
21. Boehringer-Ingelheim Pharmaceuticals, Inc., 1182.98: Safety, efficacy and pharmacokinetics of tipranavir boosted with low-dose ritonavir (APTIVUS/r) 500 mg/200 mg BID IN a racially and Gender diverse HIV-positive treatment experienced population with a pilot evaluation of therapeutic drug monitoring (TDM). (SPRING)
22. Boehringer-Ingelheim Pharmaceuticals, Inc., 1182.116 (UTILIZE): Utilization of HIV drug resistance testing in treatment experienced patients.
23. Koronis Pharmaceuticals, KP-1461-201: An Open-label, Multicenter, Mechanism Validation Study to Evaluate the Safety, Efficacy, and Tolerability of KP-1461 as Monotherapy for 124 Days in ARV-experienced, HIV-1- infected Subjects.
24. Boehringer-Ingelheim Pharmaceuticals, Inc., A Randomised, double blind, double dummy, parallel group, active controlled trial to evaluate the antiviral efficacy of 400 mg QD neVirapine Extended Release formulation in comparison to 200 mg BID ne Virapine immediate release in combination with Truvada in antiretroviral therapy naive HIV-1 infected patients (VERXVE 1100.1486)
25. GlaxoSmithKline, A randomized, open-label, parallel-group, multicenter study to determine the efficacy and long-term safety of albiglutide compared with insulin in subjects with type 2 diabetes mellitus (GLP112754)
26. GlaxoSmithKline, A randomized, double-blind, placebo- and active-controlled, parallel-group, multicenter study to determine the efficacy and safety of albiglutide when used in combination with metformin compared with metformin plus sitagliptin, metformin plus glimepiride, and metformin plus placebo in subjects with type 2 diabetes mellitus (GLP112753).
27. GlaxoSmithKline, A randomized, double-blind, placebo- and active-controlled, parallel-group, multicenter study to determine the efficacy and safety of albiglutide administered in combination with metformin and glimepiride compared with metformin plus glimepiride and placebo and with metformin plus glimepiride and pioglitazone in subjects with type 2 diabetes mellitus (GLP112757)
28. GlaxoSmithKline, A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to determine the efficacy and safety of albiglutide when used in combination with pioglitazone with or without metformin in subjects with type 2 diabetes mellitus (GLP112755)
29. Bristol-Myers Squibb Inc., A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy and safety of saxagliptin (BMS-477118) in combination with metformin in subjects with type 2 diabetes who have inadequate glycemic control on metformin alone (BMS CV181014).
30. ViiV Healthcare, Inc., SGN113399: A Phase IIb study to select a once daily oral dose of GSK2248761 in HIV-1 infected antiretroviral therapy experienced adults with non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance
31. Pfizer, Inc, A4001028: A multi-center, randomized, double-blind, placebo-controlled trial of a novel CCR5 antagonist, UK-427,857 in combination with optimized background therapy versus optimized background therapy alone for the treatment of antiretroviral-experienced HIV-1 infected subjects
32. NAPO Pharmaceutical, NP303-101: (ADVENT): Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Two-Stage Study to Assess the Efficacy and Safety of Crofelemer 125mg, 250 mg, and 500 mg Orally Twice Daily for the Treatment of HIV-Associated Diarrhea.

Ongoing:

1. Romark Laboratories, Inc., (RM08-3001): A randomized, double-blind, placebo controlled study of nitazoxanide in adults and adolescents with acute uncomplicated influenza.

Scholarly Productivity

Manuscripts for studies where I served as a site Principal Investigator

- Rosenstock J, Aguilar-Salina C, Klein E, and the **CV181-011** study team. Effect of saxagliptin monotherapy in treatment-naïve patients with Type 2 diabetes. *Curr Med Res Opin* 2009;25:2401-11. (DOI not available. PMID: 19650754).
- Calverly PM, Rabe KF, Goehring UM, M2-124 and **M2-125** study teams. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomized clinical trials. *Lancet* 2009;374:685-94. DOI: 10.1016/S0140-6736(09)61255-1.
- DeFronzo RA, Hissa MN, Garber AJ, and the **CV181-014** Study team. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes mellitus. *Diabetes Care* 2009;32:1649-55. doi: 10.2337/dc08-1984.
- Fatkenheuer G, Nelson M, Lazzarin A, **MOTIVATE 1 and MOTIVATE 2 Teams**. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. *N Engl J Med* 2008;359:1442-5. PMID: 18832245.
- Gulick RM, Lalezari J, Goodrich J, **MOTIVATE 1 and MOTIVATE 2 Teams**. Maraviroc for previously treated patients with R5 HIV-1 infection. *N Engl J Med* 2008;359:1429-41. PMID: 18832244.
- Margot NA, Lu B, Cheng A, Miller MD, **Study 903 Team**. Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903. *HIV Med* 2006;7:442-50. PMID: 16925730
- Havir DV, Koelsch KK, Strain MC, Margot NA, Lu B, **Study 903 Team**. Predictors of residual viremia in HIV-infected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudine. *J Infect Dis* 2005;191:1164-8. PMID: 15747253
- Izzedine H, Hulot JS, Vittecog D, Gallant JE, Staszewski S, **Study 903 Team**. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. *Nephrol Dial Transplant* 2005;20:743-6. PMID: 15741212.
- Gallant JE, Staszewski S, Pozniak AL, DeJesus J, Sulieman JM, **Study 903 Team**. Efficacy and safety of tenofovir DF versus stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. *J Amer Med Assoc* 2004;292:191-201.
- Hughes AR, Mosteller M, Bansal AT, Davies K, Haneline SA, **CNA30032 Study Team**. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. *Pharmacogenomics*. 2004 Mar;5(2):203-11.
- Dore GJ, Cooper DA, Pozniak AL, DeJesus E, Zhong L, **Study 903 Team**. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfecting with HIV-1 and hepatitis B virus. *J Infect Dis*. 2004 Apr 1;189(7):1185-92. Epub 2004 Mar 12.
- Gathe J, Cooper DA, Farthing CA, Jayaweerra, D, Norris D, **RESIST-1 Study Team**. Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial. *Clin Infect Dis* 2006;43:1337-46. PMID 17051503.
- McCallister S, Valdez H, Curry K, MacGregor T, Borin M, **RESIST-1 Study Team**. A 14-Day Dose-Response Study of the Efficacy, Safety, and Pharmacokinetics of the Nonpeptidic Protease Inhibitor Tipranavir in Treatment-Naive HIV-1-Infected Patients. *J Acquir Immune Defic Syndr*. 2004 Apr 20;35(4):376-382.

Book chapters:

- Clay PG**, Hewitt R. Abacavir. In: *Antimicrobial Therapy and Vaccines*. Yu VL, Edwards G, McKinnon PM, et al (eds). ESun Technologies, Pittsburgh, PA 2004. pp 467-76.
- Clay PG**, Bergen R, Letorra JL. Ribavirin. In: *Antimicrobial Therapy and Vaccines*. Yu VL, Edwards G, McKinnon PM, et al (eds). ESun Technologies, Pittsburgh, PA 2004. pp 651-62.
- Antoniou T, **Clay PG**, Tseng A. Adefovir. In: *Antimicrobial Therapy and Vaccines*. Yu VL, Edwards G, McKinnon PM, et al (eds). ESun Technologies, Pittsburgh, PA 2004. pp 533-46.

Therapeutic Reviews / Continuing Education:

- Clay PG**, Taylor TA, Glaros AG, McRae M, Williams C, McCandless D, Oelklaus M. One Pill, Once Daily: what clinicians need to know about Atripla. *Ther Clin Risk Manag* 2008;4:291-302. PMID: 18728842.
- Clay PG**, Voss LE, Williams C, Daume EC. Valid treatment options for osteoporosis and osteopenia in HIV-infected persons. *Ann Pharmacother* 2008;42:670-9. PMID: 18413693.
- El-Beyrouy C, Huang V, Darnold CJ, **Clay PG**. Poly-L-lactic acid for facial lipoatrophy in HIV. *Ann Pharmacother* 2006 Sep;40(9):1602-6. DOI 10.1345/aph.1G740
- Clay PG**, Dong BJ, Sorensen SJ, Tseng A, Romanelli F, Antoniou T. Advances in human immunodeficiency virus therapeutics. *Ann Pharmacother* 2006 Apr;40(4):704-9. DOI 10.1345/aph.1G423
- Drew RD, ACCP Infectious Diseases Practice and Research Network Bibliography Group. Key references on infectious diseases pharmacotherapy. *Pharmacotherapy* 2004;24:1586-93. DOI 10.1592/phco.24.16.1586.50954
- Clay PG**, Mangum SA. Metabolic and morphologic disorders associated with HIV infection and its therapy. *US Pharmacist* October 2002, Supplement (ACPE # 430-000-02-044-H01, Lesson 2382)

7. **Clay PG**, The abacavir hypersensitivity reaction: a review. *Clin Ther* 2002 Oct;24(10):1502-14.
8. **Clay PG**, Rathbun RC. Agrobacterium radiobacter infections: case report and review of therapeutic options. *J Infect Dis Pharmacother* 1999;4(1):7-16. DOI 10.1300/J110v04n01_03

Case Reports/Editorials/Letters to the Editor/Drug Information Rounds

1. **Clay PG***, Adiga R, Taylor TAH, Alsup R, Gerk PM, McRae MP. Post-partum pharmacokinetics of peramivir in the treatment of 2009 H1N1 influenza: a case report. (**in press**. *Obstetrics and Gynecology*, April 2011).
2. Lee MW, **Clay PG**, Kennedy K, Kennedy MJ, et.al. The essential research curriculum for doctor of pharmacy degree programs. *Pharmacotherapy* 2010;30:344e-9e.
3. **Clay PG**, Lindsey CC, Mangum SA. Reapplication requirements for prescription assistance program mischaracterized: the authors respond. *J Manag Care Pharmacy* 2007;13:687-8.
4. **Clay PG**. Single class therapy for HIV is not optimal care. *Ann Pharmacother* 2004 Jul-Aug;38(7-8):1307-9. DOI 10.1345/aph.1E030).
5. **Clay PG**, Lam AL. Testosterone replacement for the prevention of bone loss in HIV infected males. *Ann Pharmacother* 2003 Apr;37(4):582-5. DOI 10.1345/aph.1C345
6. **Clay PG**, Adams MM. Pseudo-parkinson disease secondary to ritonavir-bupirone interaction. *Ann Pharmacother* 2003 Feb;37(2):202-5. DOI 10.1345/aph.1C146
7. **Clay PG**. Using databases for clinical outcomes. *AIDS* 2002 Jan;16(2):300-3.
8. **Clay PG**, Slater LN, Rathbun RC. "Management protocol for abacavir-related hypersensitivity reactions" *Ann Pharmacother* 2000 Feb;34(2):247-9. DOI 10.1345/aph.19107
9. **Clay PG**, Rathbun RC, Slater LN. Nevirapine, lamivudine and zidovudine in HIV infected persons: The INCAS trial. Letter to the editor. *J Amer Med Assoc* 1999;281(2):130.

Book reviews

1. **Clay PG**. HIV 2nd Edition. *Ann Pharmacother* 2004;38:34.

Peer-reviewed original research, clinical observations and teaching abstracts presented

2010

1. **Clay PG**. Introducing research careers to pharmacy students: igniting a flame, not scalding for life. 2010 American Association of Colleges of Pharmacy Annual Meeting, Seattle, Washington. July 12, 2010. Session II.
2. Oliphant L, Williams C, **Clay PG**. Why am I always filling out deviation forms? A root-cause analysis of a site's protocol deviations. 46th Annual Drug Information Association, Washington, DC, June 13-17, 2010. W-22.
3. Erickson KD, Williams C, **Clay PG**. Medical records are not gospel. 46th Annual Drug Information Association, Washington, DC, June 13-17, 2010. W-01.
4. **Clay PG**, Glaros AG, Taylor TAH. Elimination of bacterial contamination following chemical treatment of medical waste using the Transposal Ultra™ fluid collection disposal system. 5th Decennial International Conference on Healthcare-Associated Infections. Atlanta, GA. March 19, 2010. Poster #190.

2009

5. **Clay PG**, Yeast J. Influence of being diagnosed HIV positive on Midwesterners spirituality. International Association of Physicians in AIDS Care 2009 Annual Conference. New Orleans, Louisiana. December 1, 2009. (No abstract number assigned).
6. Yeast J, **Clay PG**. "Spirituality of HIV-infected persons – study design and hypothesis". Lyceum 2009. Unity Village, Missouri. October 2, 2009.

2008

7. Gillenwater K, **Clay PG**. Factors that Influence the Decision to Participate in Clinical Research Trials: A Pilot Study and Model for Clinical Researchers. *Drug Information Journal* 42(4), (2008).
8. Linklater E, **Clay PG**. A pilot study to assess study participants' ability to recall information from the informed consent and how well the person who consented them perceived they would be able to recall that information. *Drug Information Journal* 2008;42(4).

2007

9. **Clay PG**, Sweet D, Godofsky E, Osiyemi O, Redfield R, Smith S, Campo R, Shrank J, Parkins J, Reno J, Becker S. KP-1461 Phase 1B: A double-blind, placebo-controlled, dose escalation study evaluating safety, tolerability, and pharmacokinetics in HIV+ adults who have failed two or more highly active antiretroviral regimens. 11th European AIDS Conference/EACS. Madrid, Spain. October 24-27, 2007. Poster #P7.2/03.
10. **Clay PG**, Sweet DE, Osiyemi OO, Godofsky E, Redfield RE, Smith SE, Campo R, Shrank JH, Parkins J, Reno J, Becker S. Safety and tolerability of KP-1461 in Phase 1, dose ranging studies in highly antiretroviral experienced HIV infected persons. Infectious Diseases Society of America 45th Annual Meeting 2007. San Diego, California. October 6, 2007. Poster #973.
11. Busscher K, **Clay PG**, Lindsey C. Cost to complete PhRMA Patient/Medication Assistance Program (PAP) Applications Using "Money Saving" Software. Kansas City University of Medicine and Biosciences Research Symposium 2007: Research for Human

Health. Kansas City, Missouri. February 9, 2007. Poster #23. (*encore* presentation at Missouri Society of Health-System Pharmacists Annual Meeting, St. Charles, Missouri, March 9, 2007. #5)

2006

12. **Clay PG.** ACCP's ID-PRN: Making YOUR membership count. How the ID-PRN enhances the value of membership. American College of Clinical Pharmacy 2006 Annual Meeting, Monterrey, California. October 28, 2006.
13. Marx JA, Lakko R, **Clay PG**, Johnston GM. Compliance with the American Heart Failure Guidelines in an Internal Medicine Residency Clinic. American College of Osteopathic Internists Research Symposium 2006. Phoenix, Arizona. October 18, 2006. (*encore* Kansas City University of Medicine and Biosciences Research Symposium 2007: Research for Human Health. Kansas City, Missouri. February 9, 2007. Poster #33) (*encore* presentation at Missouri Society of Health-System Pharmacists Annual Meeting, St. Charles, Missouri, March 9, 2007. #6).
14. **Clay PG**, Anderson P, Smith P, Lein D, Glaros A. Pharmacokinetics of once-daily fosamprenavir 1400 mg plus atazanavir 400 mg without ritonavir in HIV negative subjects. 13th Conference on Retroviruses and Opportunistic Infections, Denver, Colorado. February 6, 2006. Abstract #587 (*encore* Kansas City University of Medicine and Biosciences 2006 Research Symposium. Kansas City, Missouri. February 17, 2006. Poster #22; *encore* 2006 American College of Clinical Pharmacy Spring Research and Practice Forum. Monterrey, California. April 9, 2006.).

2005

15. Vaught ER, **Clay PG**, Glaros AG, Dietz CA, Mangum SA. Cost of Providing Medications via Prescription Assistance Programs to Medically Indigent patients. 49th Annual American Osteopathic Medical Association Meeting. Orlando, Florida. October 25, 2005. Abstract #91 (*encore* 2006 American College of Clinical Pharmacy Spring Research and Practice Forum. Monterrey, California. April 9, 2006. Abstract #181); (*encore* Kansas City University of Medicine and Biosciences 2006 Research Symposium. Kansas City, Missouri. February 17, 2006. Poster #34.).
16. Clauson KA, Glaros AG, **Clay PG**. Characteristics of healthcare providers and their assessments of dietary supplements. American College of Clinical Pharmacy 2005 Spring Practice and Research Forum, April 10-13, Myrtle Beach, SC.
17. Sudholdt WF, **Clay PG**, Kirila CK, Johnston GM. Elevated colon cancer rates detected despite failing to screen to American Cancer Society goal. American College of Osteopathic Internists Research Symposium 2005. Orlando, Florida. October 17, 2005.
18. Clauson KA, **Clay PG**, Glaros AG. Perceived efficacy, indications and information sources for dietary supplements in medically indigent patients and their healthcare providers. Kansas City Area Life Sciences Institute Research Day, Overland Park, Kansas. April 6, 2005. E-25.

2004

19. **Clay PG**, Campo R, DeHovitz J, Johnson D, Squires K, Jordan W, Sajjan S, et al. HIV patient worries and sources of influences on intent to take newly prescribed medications: analysis by age. 27th Society of General Internal Medicine. Chicago, Il., May 15, 2004. Poster #80.
20. Sutton SS, **Clay PG**, Oppelt TF, Mullenix TA, Best CL. Predicting coronary heart disease in human immunodeficiency virus infected patients. 2nd International Conference on Clinical Pharmacy, Paris, France, April 28, 2004.

2003

21. **Clay PG.** Actual doses per day in patients with successful antiretroviral regimens. 2nd International Conference on Adherence to Antiretrovirals. Omni Renaissance Conference Center, Dallas, Texas. December 5, 2003. [*platform presentation, Abstract #8*]
22. DeHovitz J, Johnson D, **Clay PG**, Squires K, Jordan W, Campo R, Thompson D, et al. Factors Associated with Medication Worries in HIV Patients on Antiretroviral Therapy (ART). 41st Annual Infectious Disease Society of America Meeting. San Diego, California, October 11, 2003. Abstract #663.
23. Campo R, Johnson D, **Clay PG**, DeHovitz J, Squires K, Jordan W, Thompson D, et al. Willingness to Accept Antiretroviral Therapy (ART) Change Recommendations. 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois. September 15, 2003. Poster #H-854.
24. Jordan W, Campo R, Dehovitz J, **Clay PG**, Johnson D, Squires K, et al. Impact of patient's HIV knowledge on medication adherence, general health perception and patient worries. 26th Annual Meeting for the General Internal Medicine Society, Vancouver, Canada April 2003, Poster #47.

2002

25. **Clay PG**, Lein AD. Retrospective and concurrent comparison of the efficacy and cost-effectiveness of topical testosterone gel (TG) versus intramuscular (IM) or dermal patches (DP) in medically indigent HIV infected patients with clinical hypogonadism (HG) or laboratory evidence of need for testosterone supplementation (TS). 40th Infectious Diseases Society of America Meeting, Chicago, IL October 2002, Poster #474.
26. **Clay PG**, Mangum SA. Successful strategies at enhancing chapter enrollment through utilization of national association assistance. 2002 Annual American College of Clinical Pharmacy, Albuquerque, NM, October 2002.
27. **Clay PG**, Clauson KA, Glaros A. Pilot, Observational Study to Assess the Frequency, Indications, Effectiveness and Types of Complementary and Alternative Medicine (CAM) including Herbal and Natural Products Utilized in HIV infected versus non-HIV infected Medically-indigent and Minority patients. 2002 Society of Infectious Disease Pharmacists Annual Meeting, San Diego, CA, September 2002.

2001

28. **Clay PG**, Clauson KA. Use of complementary and alternative medicine (CAM) in the literature: who is missing and why. 2001 American College of Clinical Pharmacy Annual Meeting, Tampa, Fl. October 2001, Poster #105
29. **Clay PG**, Boyd J, Roberts N. Disparity in HIV medication initiation in African-American patients in a medically indigent population. 2001 American College of Clinical Pharmacy Annual Meeting, Tampa, Fl. October 2001, Poster 108e
30. Butcher D, **Clay PG**, Jordan W, Stansell J, Campo R, Dehovitz J, et al. HIV-related knowledge in patients treated with antiretroviral therapy (ART). 40th Annual Infectious Diseases Society of America meeting, San Francisco, Ca. October 2001.
31. Dehovitz J, Campo R, Butcher D, **Clay PG**, Jordan W, Stansell J, Grimes C, et al. General Health Perception of Patients with HIV. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL. September 2001.
32. Campo R, Dehovitz J, Butcher D, **Clay PG**, Jordan W, Stansell J, Rosa I, et al. Patient Willingness to Accept Antiretroviral Therapy (ART) Change Recommendations. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL. September 2001.

2000

33. **Clay PG**, Kille A. "Comparison of the Incidence, Magnitude, Rate and Post-Therapeutic Effect of Ritonavir (RTV) on Cholesterol and Triglycerides (CHOL/TG) when used as a Pharmacokinetic Inhibitor (200 mg BID) versus Antiretroviral (400 mg BID)" 40th ICAAC, Toronto, Ontario, Canada (September 18, 2000) (*encore* 35th ASHP Midyear Clinical Meeting, Las Vegas, NV (December 6, 2000)); (*encore* 1st Annual Students Engaged in Artistic and Academic Research, UMKC, Kansas City, Mo (May 3, 2001))
34. **Clay PG**, Boyd J, Roberts N. "Disparity in HIV medication initiation in African-American patients in a medically indigent population" 40th ICAAC, Toronto, Ontario, Canada (September 17, 2000)
35. **Clay PG**, Adams MA, Mangum E. "Severe Pseudoparkinsonism secondary to a ritonavir-buspirone interaction" 38th IDSA, New Orleans, Louisiana (September 8, 2000)

1999

36. **Clay PG**, Slater LN, Rathbun RC, Farmer KC. "Cost avoidance of care for HIV patients through clinical trials" 39th ICAAC, San Francisco, CA (September 25, 1999).

Service

Government service

State

- 12/07 – 12/10 Voting member, Missouri Technology Commission High-Tech Small Business Incentive Program Advisory Committee, Kansas City, Missouri
- 2008 University of Louisiana – Monroe School of Pharmacy, External Grant Reviewer

Federal

- 1987 – 1993 Louisiana Army National Guard 256th Infantry Brigade (Tactical operations center operations sergeant; security detachment, Battalion S-3, Operation Desert Storm)
- 10/08 – 10/11 Voting Member (3 year appointment), United States Department of Health and Human Services (DHHS), Food and Drug Administration (FDA) Center for Drug Evaluation and Research's (CDER) Antiviral Advisory Committee, Silver Springs, Maryland.
- 2008 DHHS NIH NIAID Special Emphasis Panel (P01 ZA11-CCH-A-M1)
- 2009 DHHS NIH ARRA Challenge Grants (2 panels)
- 2011 DHHS, NIH NIAID Special Emphasis Panel Review Group (BAA 05 ZA11 EC-M (C1))
- 2001 – ONG DHHS FDA CDER, Pharmacology consultant (all committees), Silver Springs, Maryland.

International:

- 2006 Grant reviewer, Republic of South Africa Medical Research Council

Promotion and Tenure External Reviewer

- 2007 Western University of Health Sciences, College of Pharmacy
- 2008 University of Oklahoma Health Sciences Center
- 2010 University of South Carolina, College of Pharmacy
- 2011 Western University of Health Sciences, College of Pharmacy

Peer-Reviewed Journal Referee activities:

Editorial role, Annals of Pharmacotherapy, section on HIV/AIDS and STDs

- 2003 – 2007 Chairperson
- 2007 – 2009 Contributing member

Peer reviewed journal manuscript reviewer:

Annals of Pharmacotherapy (1998 – ONG)	Clinical Therapeutics (2001 – ONG)
Journal of American Pharmaceutical Association (2001 – ONG)	Pharmacy Practice News (2003 – ONG)
Pharmacotherapy (2004 – ONG)	Journal of General Internal Medicine (2004 – ONG)
International Journal of Pharmaceutical Medicine (2006 – ONG)	Current Drug Therapy (2006 – ONG)
Future Medicine (2008 – ONG)	Pharmacogenomics (2008 – ONG)
Pharmacy Practice (2008 – ONG)	HIV Clinical Trials (2008 – ONG)
Clin Interv Aging (2008 – ONG)	J Health Care for the Poor and Underserved (2008 – ONG)
Insulin (2009 – ONG)	AIDS Research and Human Retroviruses (2008 – ONG)
J Acquired Immune Defic (2009 – ONG)	Pharmacist's / Prescriber Letter (2010 – ONG)
Curr Med Res and Opin (2005 –ONG)	

Professional Organizations Offices Held / Leadership Roles:

American Association of Colleges of Pharmacy

- 2001 – 2003 Member, Ad Hoc Committee, Computer Technology in Pharmacy Practice Education (nationwide survey developed, implemented, completed and reported at 2003 annual meeting)
- 2008 2008 New Investigator Program, Grant Review Committee, Pharmacy Practice
- 2009 – 2010 Member, Research and Scholarship Task Force

American College of Clinical Pharmacy:

- 2000 – 2001 Member, Awards Committee
Chairperson, Sub-committee on Clinical Practice Award
- 2001 – 2002 Member, Task Force on Cultural Competence
- 2001 – ONG Spring meeting abstract reviewer
- 2001 – ONG Annual meeting abstract reviewer
- 2002 – 2006 Annual meeting Silent Auction volunteer
- 2007 Member, Organizational Affairs Committee
- 2008 – 2009 Member, Taskforce on the state of Research in the pharmacy curriculum
Infectious Diseases Practice and Research Network (a specialty group within ACCP)
- 2003 – 2004 Secretary/Treasurer
- 2004 Member, Mini-sabbatical Review Committee
- 2004 – 2005 Chair-elect
- 2005 – 2006 Chair
- 2006 Chairperson, Ad-Hoc Committee for Revision of Mini-Sabbatical Application Guideline
- 2006 – 2007 Past-chair
- 2007 Chairperson, Mini-Sabbatical Review Committee

American Pharmacists Association

- 2009 - ONG Abstract reviewer
- 2009 – 2011 Member, Executive Council, APRS
- 2009 – 2010 Judge, Scientific Poster Sessions, Annual Meeting
- 2009 – 2010 Chair-Elect, APRS Section on Clinical Sciences
- 2009 - 2010 House of Delegate representative, APRS – Clinical Sciences section
- 2010 – 2011 Chair, APRS Awards Committee
- 2010 – 2011 Chair, APRS Section on Clinical Sciences

American Society of Health-System Pharmacists

- 1999 – ONG Contributing member, Clinical Specialist Network
- 2002 – ONG Contributing member, HIV Specialist network
- 2002 Member, Advisory Panel on Computers in Teaching
- 2003 Case contributor and critical reviewer, ASHP Clinical Skills Competition, New Orleans, La. December 2003.
- 2004 Candidate, ASHP Section on Clinical Specialists and Scientists

Heartland Association of Research Professionals

- 2010 – 2011 Vice-President
- 2011 Chair, Annual Conference

International Pharmaceutical Federation

- 2002 Module reviewer, Role of Pharmacists in Providing Pharmaceutical Care to HIV infected persons' modular learning sets

Kansas City Association of Nurses in AIDS Care:

- 2000 – 2002 Co-chair, Scientific Affairs and Events

Mid-America College of Clinical Pharmacy:

- 2001 – 2002 President - elect
- 2002 – 2003 President
- 2003 – 2006 Website administrator
- 2005 – ONG Acting President

Missouri Society of Health-System Pharmacists

- 2001 – 2008 Research and Education Foundation Board Member
- 2003 – 2006 Website development/oversight task force
- 2009 Planning Committee, Annual Meeting
- 2009 Judge, Resident Poster competition

Society of Infectious Disease Pharmacists:

2001 – 2002 Member, Internet Committee
 2002 – 2004 Chair, Internet Committee
 2002 – 2005 Co-Chair, Task Force on HIV Focused Pharmacists
 2004 Candidate, Board Member at Large
 2006 Member, Program Committee, 2006 SIDP Annual Meeting
 2007 Member, Membership Committee
 2008 Member, Government Affairs
 2008 Chair, Recognition Committee
 2009 – 2011 Member, Political Advocacy Committee

2nd International Conference on Adherence to Antiretroviral Therapy

2003 Abstract reviewer

Conferences/programs for which I served as chair or member of conference organizing body:

Dec 2010 2nd Global Clinical Budgeting and Contracting Excellence Conference, a 2-day annual symposium delivering timely and relevant information on improving the contractual process between clinical trial sponsors, CROs and investigator sites, Philadelphia, PA.

Apr 2009 MSHP/ISHP Annual Meeting Planning Committee, a 3 day annual meeting of two states' of pharmacy association meeting, St. Charles, Missouri.

Feb 2008 KCUMB 17th Annual Research Day, Conference Chair – 1 ½ day intramural research presentation conference focusing on student and faculty research activities including keynote speaker from NIH (Dr. Victoria Pinn). Kansas City, Missouri.

Apr 2004 “HIV in Kansas City – whaddya gonna do ‘bout it?” – 4-hour media outlet focused informational symposium on ongoing HIV research in the Kansas City Metropolitan Service Area

Jun 2003 National Pharmacist Advisory Panel: Two day conference in Del Mar, California designed to update and gather feedback on HIV Pharmacotherapy with leading pharmacy researchers and clinicians from across the United States

June 2003 “Drugs and Bugs: Infectious Microorganisms”, Missouri Biotechnology Association, Assisted in coordinating event and finalizing speakers for UMKC coordinated event, Kansas City, MO

Oct 2002 Mid-America College of Clinical Pharmacy CE program “HIT: sorting out the controversies” – 1 hour CE program

Aug 2002 Kansas City Association of Nurses in AIDS Care 14th World AIDS Conference Summary: 4-hour symposium conducted by internationally known speakers and researchers in HIV. Funding directly provided to KC ANAC

Aug 2002 Mid-America and Gateway Colleges of Clinical Pharmacy Annual Meeting entitled “Cutting Edge Pharmacotherapy – Innovations in Practice and Medicine”, Branson, Missouri. Funding provided directly to MACCP

Jun 2002 Mid-America College of Clinical Pharmacy Symposia on “What PHARMA looks for in seeking clinical trial sites”, Kansas City Royals Kaufmann stadium, Kansas City, Missouri.

Oct 2000 Mid-America AIDS Educational Alliance (MAEDAL): multidisciplinary, educational breakfast meeting of HIV researchers in the Kansas City area with presentations from locally-based & nationally known researchers/clinicians

Teaching

Undergraduate / Graduate audiences, Academic-based

Didactic teaching

- 1999 – 2005 UMKC COP, PharmD program, course coordinator for several years
- 1999 – 2005 UMKC College of Nursing, Master's of Nursing Practitioner program: nursing therapeutics
- 2005 – ONG KCUMB COM/B, Pharmacology/ethics, Clinical research training and ethics on conducting clinical research

Clinical/Experiential Teaching

- 1999 – 2005 UMKC COP, PharmD program, required medicine & elective research rotations (students, residents and non-traditional)
- 2006 – ONG UMKC COP, PharmD program, 4-week elective in clinical research
- 2007 – ONG KCUMB COM/B, 4-week elective rotations in clinical research for medical and master's students
- 2009 – ONG St. Louis College of Pharmacy, PharmD program, 5-week elective course in clinical research
- 2010 – ONG KCUMB COM, IDIS-122 (a 1.5 credit hour course I designed to provide thorough education to medical students regarding the appropriate, ethical and economical aspects of clinical research)

Group Facilitating Sessions

- 1999 – 2004 UMKC COP, Honors seminar, elective course for senior PharmD students
- 1999 – 2005 UMKC COP PharmD program, led and guided various sized groups of students in non-classroom settings discussing introduction to pharmacy and research methodology
- 2006 – ONG KCUMB COM, quarterly small group sessions discussing professionalism, ethical and cultural topics

Graduate Student Teaching

- 2005 – ONG KCUMB COM, Summer Fellowship program (annual, 2 month intensive research experience for medical students)
- 2007 KCUMB COB, served as primary mentor for master's thesis committee

Invited Lectures

- 2004 University of Nebraska College of Pharmacy (2004, Guest therapeutics lecturer (HIV/AIDS)
- 2003 University of Kansas School of Pharmacy and Kansas University Medical Center, Post-doctoral Pharmacy Practice/Masters of Business Administration resident rotations
- 2008 St. Louis University College of Pharmacy, St. Louis, Missouri, Clinical Research Elective Rotation for senior PharmD students

Professional / Healthcare provider instruction

Professional conference invited speaker and platform presentations:

1. "Understanding how facilitated clinical research can represent a successful component of your medical practice", KCUMB 19th Annual Research Day, Kansas City, MO, April 19, 2011.
2. "Building a flexible contract to enable patient recruitment and avoid trial delays", 2nd Annual Global Clinical Budgeting & Contracting Excellence Conference, Philadelphia, PA, December 7, 2010.
3. "Sponsor, site and CROs discuss improving communication, adhering to contracting and budgeting responsibilities and building relationships to achieve success: the academic site perspective", 2nd Annual Global Clinical Budgeting & Contracting Excellence Conference, Philadelphia, PA, December 6, 2010.
4. "Patient Protection and Affordable Care Act 2010: Impact on research", 2010 Heartland Association of Clinical Professionals, Overland Park, KS, October 15, 2010.
5. "HIV in 2010: translating research advances and guideline updates into patient care", 20th Annual Society of Infectious Diseases Pharmacists Annual Meeting, Boston, MA, September 11, 2010.
6. "Drug Development Panel: Powering Antiretroviral Regimens to Ameliorate Adherence Concerns", Session Moderator and presenter, 5th International Conference on HIV Treatment Adherence, Miami, Florida, May 25, 2010.
7. "Determining a Common Ground: Identifying Fair Practices for Intellectual Property Rights when Contracting with Academic Medical Centers", eXI PhRMA Global Budgeting & Contracting Conference, Princeton, New Jersey, December 8, 2009.
8. "Recruiting Niche Populations", Heartland Area Research Professionals Annual Educational Conference, Overland Park, Kansas, October 30, 2009.
9. "Blinding in the Age of Blogging", Heartland Area Research Professionals Annual Educational Conference, Overland Park, Kansas, October 30, 2009.
10. "The influence of HIV infection on religion and spirituality", LYCEUM 2009, Unity Village, Missouri, October 2, 2009.
11. "Update on Antiretrovirals: 2009", Missouri/Illinois Society of Health-System Pharmacists Annual Meeting, St. Charles, Missouri, April 25, 2009.
12. "Once Daily Antiretroviral Regimens", 2009 American College of Clinical Pharmacy/European College of Clinical Pharmacy Annual Meeting, Orlando, Florida, April 28, 2009.

13. "Clinical Trials and the Research Pyramid", 17th Annual KCUMB Research Symposium, Kansas City, Missouri, February 17, 2009.
14. "Mentoring the research professional", 2009 American Pharmacists Association Annual Meeting, San Antonio, Texas, April 6, 2009.
15. "Optimizing Subject Recruitment for Clinical Trials", Shriner's Hospital Annual Research Conference, Tampa, Florida, January 17, 2009.
16. "Getting from Plan to Point of Care: Local Implementation of a Global Strategic Recruitment Plan", Drug Information Association interactive webinar, November 13, 2008.
17. "Delivering PAP Programs – Understanding The Prescriber's Burden", Modernize Patient Assistance Programs, Washington, DC, September 18, 2008.
18. "HIV Management Update: 2009", 3 hour seminar to Walgreen's pharmacists, Walgreen's TMC, Kansas City, Missouri, August 19, 2008.
19. "Recognizing the Controversies, Impediments and Opportunities for Patient Recruitment within specific Therapeutic Areas: HIV/Infectious Disease", eXI Pharma's Tools for Meeting Patient Recruitment Goals, Baltimore, Maryland, July 28, 2008.
20. "Successfully Recruiting Niche Populations for Clinical Trials: God, Money and Me – the influence of religion, economics and ethnicity on recruitment strategies targeting under-represented populations", 44th Annual Meeting of the Drug Information Association, Boston, Massachusetts, June 26, 2008.
21. "HIV Therapeutic Management: Antiretroviral, Opportunistic Infections, Drug Interactions and Co-Morbid diseases", 3-hour seminar to Walgreen's pharmacy interns, Walgreen's District Office, Fairway, Kansas, June 19, 2008.
22. "HIV Therapeutic Update: 2009", 2008 Annual MSHP/ISHP Meeting, St. Charles, Missouri, April 25, 2008.
23. "Invigorating clinical research productivity from clinicians – lessons learned at Dybedal Clinical Research Center", Grand Rounds, University of Buffalo School of Pharmacy, Buffalo, New York, March 27, 2008.
24. "HIV research directions in Kansas City – initiatives, directions and prospects", UMKC Dental School Oral Biology Grand Rounds, Kansas City, Missouri, January 16, 2008.
25. "Emerging Therapeutic Options: New Twists for the Clinical Management of Patients with HIV/AIDS", 2007 American College of Clinical Pharmacy Annual Meeting CME, Denver, Colorado, October 16, 2007.
26. "Incorporating Clinical Research into Clinical Practice". KCUMB Homecoming CME conference, Kansas City, Missouri, September 7, 2007.
27. "Organizing Clinical Research", KCUMB Winter CME Seminar, Kansas City, Missouri, December 16, 2006.
28. "Translational Research", Kansas City Area Life Sciences Institute-Meeting of the Scientific Advisory Committee, Kansas City, Missouri, November 28, 2006.
29. "Health Disparities in HIV", 2006 American College of Clinical Pharmacy Annual Meeting CME, St. Louis, Missouri, October 28, 2006.
30. "Antiretroviral Pharmacotherapy: 2006", ACCP 2006 Annual Meeting Satellite Symposium sponsored by Gilead Sciences and conducted by University of Buffalo, St. Louis, Missouri, October 27, 2005.
31. Moderator, "Therapeutic Updates and Controversies in Infectious Diseases", ACCP 2006 Annual Meeting, St. Louis, Missouri, October 26, 2006.
32. Moderator, "HIV Pharmacotherapy: An Update for the Practicing Clinician (and Occasional HIV Pharmacist)", ACCP 2006 Annual Meeting, St. Louis, Missouri, October 25, 2006.
33. "State of the Art Mini-Review: Influenza", ACCP 2006 Annual Meeting, St. Louis, Missouri, October 26, 2005.
34. "Antiretroviral Update: 2006", KCUMB Homecoming 2006 CME Seminar, Kansas City, Missouri, September 7, 2006.
35. "Is There a Future for Structured Treatment Interruptions?", IAPAC North American Sessions 2006 CME, Chicago, Illinois, May 11, 2006.
36. "Pharmacologic Management of HIV and AIDS: Antiretrovirals", KSHP-MSHP Spring meeting '06 CME, "Spring Into Action", Overland Park, Kansas, Friday, April 21, 2006.
37. "Testosterone Deficiency: Defining the Problem and Treating it Effectively", Medical Center of Independence Conference CME. February 15, 2006.
38. "Research from Head to Toe: Enrolling Your Patient's in Investigational Studies Available at KCUMB's Dybedal Clinical Research Center", Medical Center of Independence Conference. November 30, 2005.
39. "Developing Clinical Research", KCUMB Lunch and Learn Series CME, Kansas City, Missouri, November 4, 2005.
40. "HIV Pharmacotherapy: 2005 Update", ACCP 2005 Annual Meeting Satellite Symposium sponsored by Gilead Sciences and conducted by University of Buffalo, Monterey, California, October 24, 2005.
41. Moderator, "Antifungal Update: A Little Bit for Everyone", ACCP 2005 Annual Meeting, San Francisco, California, October 23, 2005.
42. "The Midas Touch? Turning Practice into Research Dollars", KCUMB Homecoming 2005 CME Seminar, Kansas City, Missouri, September 9, 2005.
43. Moderator, "Deconstructing Data", North American AIDS Treatment Action Forum, St. Louis, Missouri, December 10, 2004.
44. "Practical approaches to manage and prevent multi-drug resistant infections: HIV" – 2004 ASHP Midyear Clinical Meeting, Orlando, FL. December 9, 2004.
45. "TDM in HIV: Update 2004" – Springfield, Missouri, November 3, 2004.

46. "Published data on TDM of Antiretroviral Therapy" – Grand Rounds, Grady Memorial Hospital, Atlanta, Georgia, October 14, 2004.
47. "ABCs of Pharmacokinetics" – 1 hour ACPE accredited program, Springfield, Missouri, October 6, 2004.
48. "Pharmacokinetics of antiretrovirals in 2004 – a review of the published data" – 1 hr. CME accredited program, Landry's Restaurant, El Paso, TX, August 25, 2004.
49. "Update on pharmacokinetic considerations in HIV management" – University of Illinois – Chicago Mid-America AIDS Education and Training, Chicago, IL, August 4, 2004.
50. "Reyataz: the first once daily protease inhibitor" – Kansas City, Mo. July 28, 2004
51. "Treatment strategies in antiretroviral experienced patients" – McCauley Health Clinic, Grand Rapids, MI, June 15, 2004.
52. "Emerging Issues in HIV Therapy" – University of South Florida and Florida/Caribbean AIDS Education Training Center continuing education program, Orlando, Florida, June 5, 2004.
53. "A discussion on efavirenz (Sustiva)" – Kansas City, MO, May 27, 2004.
54. "Managing Drug Interactions of Antiretrovirals" – University of Houston's 2004 Infectious Disease Pharmacotherapy Symposium, Houston, TX. May 21, 2004.
55. "The pharmacokinetics of antiretrovirals: a primer for fellows" – Henry Ford Hospital Division of Infectious Diseases and Hospital Epidemiology Grand Rounds, Detroit, MI. April 28, 2004.
56. "Examining the pharmacoconomics of US AIDS drug access: treatment considerations" – International Association of Physicians in AIDS Care summit on access to antiretrovirals, Washington, D.C. April 6, 2004.
57. "HIV drug interactions" – 8th Annual Infectious Disease and Critical Care Symposium, Detroit Medical Center, Wayne State University, Detroit, MI. January 30, 2004.
58. "5 Minute Clinical Pearls: - How to lose an antiretroviral in 10 days" – American Society of Health-System Pharmacists Mid-Year Clinical Meeting, New Orleans, Louisiana, December 7, 2003.
59. "The Perfect Storm: resistance to anti-infectives in 2003" – American Society of Health-System Pharmacists Mid-Year Clinical Meeting, New Orleans, Louisiana, December 6, 2003.
60. "Making sense of the latest antiretrovirals – for health professionals: click here!" – pharmacist CE evening program, Detroit, MI October 9, 2003.
61. "HIV Pharmacotherapy: ICAAC and IAS highlights – a pharmacist's perspective" – lunchtime educational session, Detroit, MI October 9, 2003.
62. "Antiretroviral Pharmacotherapy, 2003's IAS and ICAAC Updates" – Grand Rapids, MI. September 30, 2003.
63. "Antiretroviral resistance: translating bench to bedside" – Division of Pharmaceutical Sciences Seminar Series, UMKC School of Pharmacy, Kansas City, MO September 25, 2003.
64. "Antiretroviral Pharmacokinetics: Translating Bench to Bedside" – Florida AIDS Education and Training Program, Embassy Suites, Orlando, Fl. August 2, 2003.
65. "HIV Pharmacotherapy: A Primer" – L'Auberge Resort and Spa, Del Mar, California, June 13, 2003
66. "Update on HIV Therapy" – Chicago Veteran's Affairs Medical Center, May 29, 2003, Chicago, IL.
67. "Emerging Trends in HIV Therapy: the role of therapeutic drug monitoring and pharmacokinetics on clinical outcomes" – CE program, May 29, 2003, Chicago, IL.
68. "Simplifying the ART of HAART: applying pharmacokinetics to antiretroviral therapy" – Agouron/Pfizer National Sales Meeting, Coronado Island, California March 12, 2003.
69. "Developing Contracts with the Pharmaceutical Industry", Workshop on Improving Research Funding, Sponsored Programs and Research Support Office, UMKC Office of Research Administration, November 11, 2002
70. "Metabolic and morphologic complications of HIV and its therapy" – Mid-America AIDS Educational and Training Center, November 6, 2002, Milwaukee, WI.
71. "HIV Acronyms: what do they mean and why should I care?" – Mid-America/Gateway Colleges of Clinical Pharmacy 8th Annual Joint meeting, August 4, 2002, Branson, Mo.
72. "Managing Drug Interactions in HIV" – University of Buffalo at New York's HIV Pharmacotherapy Network HIV Pharmacist Certificate Program. April 3, 2002, West Palm Beach, Florida
73. "Antiretroviral therapy guidelines – 2002 Edition" – University of Buffalo at New York's HIV Pharmacotherapy Network CE program, April 4, 2002, West Palm Beach, Florida.
74. "Therapeutic Drug Monitoring in HIV Pharmacotherapy: A Clinician's Perspective" – Clinical Pharmacology in Antiretroviral Therapy, December 15, 2001, Chicago, IL.
75. "Making Sense of HIV Pharmacotherapy: Update 2001" – University Learning Systems, Kissimmee, FL (December 8, 2001); 4-hours continuing education program
76. "TDM in HIV – Making sense of it all" – Agouron sponsored CE program, Ft. Lauderdale, Florida, December 6, 2001.
77. "Pharmacoconomics of HIV" – Academy of Continuing Education, Ft. Lauderdale, Florida (April 2001)
78. "Making Sense of HIV Pharmacotherapy" – MSHP/ISHP Annual Meeting, St. Louis, Mo (March 2001)
79. "Retrovirus 2001: An update" – Kansas City Infectious Disease Society, Kansas City, Mo (February 2001)
80. "Controversies in HIV Management: Debating the issues" – MACCP, Kansas City, Mo (June 2000)

81. “Pharmacoeconomic considerations in HIV Pharmacotherapy” Academy of Continuing Education Programs, Atlanta, Georgia (May 2000)
82. “Update in HIV Pharmacotherapy” Academy of Managed Care Pharmacy Annual Meeting, Phoenix, AZ (March 2000)
83. “Update on HIV Pharmacotherapy” – UMKC School of Medicine, Kansas City, Mo (November 1999)
84. “Finding Waldo: Selecting optimal therapy for HIV infected persons in 1999” Academy of Managed Care Pharmacy Annual Meeting, Atlanta, Georgia (October 1999)

Mass media/provider & patient educational publications (non-peer reviewed)

1. **Clay PG.** With diabetes, actions speak louder than words. (*in press. Posit Aware. March 2011*).
2. **Clay PG.** A bad break: bone issues in people with HIV: what we’ve learned so far and what you can do. *Posit Aware* 2010. Jan/Feb;32-3.
3. Oelklaus MW, Williams CL, **Clay PG.** Managing long-term Side Effects of HIV Therapy. *Posit Aware* 2007 Mar-Apr;18(2):33-34. PMID: 17390489.
4. **Clay PG,** Clifton CE, Berry J, eds. Pharmacokinetics in HIV: A Primer for Patients. *Posit Aware* (two part series intended to educate patients about their antiretroviral pharmacokinetics). 2005 Winter.
5. **Clay PG.** The nukes. Each one works a little differently. *Posit Aware* 2005 Winter; Spec No:8-11.
6. **Clay PG.** What’s PK (pharmacokinetics) got to do with it? Supplement introduction. *Posit Aware* 2005 Winter;No:2-3.
7. **Clay PG,** Smith RS, eds. Dosing chart for boosted protease inhibitor regimens. *J Intern Assoc Physic AIDS Care.* Jun 2004.
8. **Clay PG.** Adherence conference: Elements of success. *Posit Aware* 2004 Mar;15(2):16-7.
9. **Clay PG.** 11th Annual Retrovirus Conference. Drug update: the old, the new, the still to come. *Posit Aware* 2004;15:25-7.
10. **Clay PG.** The 8th Annual HIV Drug Guide. *Posit Aware* 2004;15:16-42.
11. **Clay PG.** Bon appétit: using food to boost your Viracept. *Posit Aware* 2003;14:29.
12. **Clay PG.** The 7th Annual HIV Drug Medication Guide. *Posit Aware* 2003Jul-Aug;13(4);12-30.
13. **Clay PG.** Mixing and matching meds: ICAAC Update. *Posit Aware* 2002;12;12-6.
14. **Clay PG.** Retrovirus update. *Posit Aware* 2002 May-Jun;13(3);30-1.

Community and patient support group invited educational panels / sessions:

1. “HIV Medicines: 101”, 1 hour educational seminar provided to medically-indigent and minority HIV infected women (Healthy University), Kansas City, Kansas, May 2, 2011.
2. “HIV Research 101 for Women: questions to ask and answers you should get”, HIV University Annual Women’s Conference, Kansas City, KS, November 6, 2010.
3. “HIV Research: Questions you need to ask”, Pozitive Perspectives, Springfield, MO, October 12, 2010.
4. “An update on HIV medicines: 2010”, RAISE Annual Client Educational Conference, St. Joseph, MO, October 10, 2010.
5. “HIV – what else do you need to worry about besides the virus? A review of the complications of being HIV-positive”, RAISE Annual Client Educational Conference, St. Joseph, Missouri, October 10, 2009.
6. “HIV Medicines: 101”, 1 hour educational seminar provided to medically indigent and minority HIV infected women (HIV-U), Kansas City, Kansas, May 14, 2009.
7. “What is clinical research and how do you refer your patients to appropriate trials? A primer for primary care”, St. Joseph Carondelet Medical Center KCUMB-PA clinic, Kansas City, Missouri, August 29, 2008.
8. “Yes – you CAN be a pharmacist!”, Multiple presentations at local school district career day, DeSoto School District, Shawnee, Kansas, April 16, 2009.
9. “New and Emerging Therapies in HIV: A Patient’s Town Hall Meeting”, International Association of Physician’s in AIDS Care organized, Kansas City, Missouri, November 18, 2008.
10. “Understanding your HIV medicines and why they make you feel so bad sometimes”, 3 hour presentation and discussion with Phoenix Project (community group of HIV-positive African-American men), Tan-Tar-A Resort, Osage Beach, Missouri, August 24, 2008.
11. “HIV research in Kansas City”, presentation to Kansas City’s Ryan White Planning Council, Kansas City Health Department, Kansas City, Missouri, June 18, 2008.
12. “HIV Medicines: 101”, 1 hour educational seminar provided to medically indigent and minority HIV infected women (HIV-U), Kansas City, Kansas, May 21, 2008.
13. “Opportunistic Infections in HIV patients: Update 2009”, 1 hour educational program for HIV Case Managers, Good Samaritan Project, Kansas City, Missouri, April 23, 2008.
14. “Yes – you CAN be a pharmacist!”, Multiple presentations at local school district career day, DeSoto School District, Shawnee, Kansas, April 17, 2008.
15. “How to find and refer patients to appropriate clinical trials: a primer for primary care”, AIDS Project of the Ozarks, Springfield, Missouri, April 10, 2008.
16. “HIV Update for Case Managers”, 1 hour educational session to HIV case managers, Good Samaritan Project, Kansas City, Missouri, February 28, 2008.

17. "HIV Update for Case Managers", 1 hour educational session to HIV case managers, St. Joseph, Missouri, (RAISE), February 26, 2008.
18. "HIV Update for Case Managers", 1 hour educational session to HIV case managers, Topeka AIDS Project, Topeka, Kansas, February 18, 2008.
19. "What do you need to know about clinical research?", 1 hour presentation to HIV case managers, Douglas County AIDS Project, Lawrence, Kansas, December 18, 2007.
20. "Updating HIV medications for case managers", 1 hour educational seminar to HIV case managers, Good Samaritan Project, Kansas City, Missouri, November 14, 2007.
21. "Update on HIV therapy – new agents", 1 hour educational seminar to HIV positive persons, RAISE, St. Joseph, Missouri, October 20, 2007.
22. "HIV Medications – why are you taking what you are taking?", 1 hour presentation for HIV positive persons, Gregg Klice Community Center, Kansas City, Missouri, October 19, 2007.
23. "HIV Therapeutics Update: 2007", 1 hour educational seminar for case managers, AIDS Project of the Ozarks, Springfield, Missouri, September 12, 2007.
24. "HIV Medications and U: Side Effects" – 1 hour educational seminar provided to medically indigent and minority HIV infected women (HIV-U), Kansas City, Missouri, August 20, 2007.
25. "HIV Therapy Update for Case Managers", 1 hour educational seminar to HIV case managers, Regional AIDS Interfaith Network, Columbia, Missouri, June 26, 2007.
26. "Emerging Therapies for HIV" – 1 hour educational seminar to HIV positive persons, St. Joseph, Missouri, May 30, 2007.
27. "HIV Medications and U: What are the medicines?" – 1 hour educational seminar provided to medically indigent and minority HIV infected women (HIV-U), Kansas City, Missouri, May 17, 2007.
28. "Update on HIV Therapy: 2007", Good Samaritan Project Case Manager monthly meeting, Kansas City, Missouri, January 22, 2007.
29. New Clinic Research presentation provided to the Women of Hope group at Truman Medical Center, Kansas City, Missouri, August 16, 2006.
30. HIV in Africa – what are the risks for mission workers? – educational seminar provided to Country Club Christian Church mission workers, Kansas City, Missouri, November 17, 2004.
31. "HIV in Kansas City: Whaddya goin' do 'bout it?" – organized and conducted a press/media conference to promote local HIV researchers to present ongoing HIV research, counseling and testing activities in the Kansas City Metropolitan Service Area. April 30, 2004.
32. "HIV Medications – where are we in 2003?" – 1 hour educational seminar provided to Kansas City wide case manager / social worker conference, Kansas City Health Department, Kansas City, MO September 29, 2003
33. "HIV Medications – side effects" – 1 hour educational seminar provided to medically indigent and minority HIV infected women in Kansas City, MO, September 26, 2003.
34. "HIV Medications – the basics" – 1 hour educational seminar provided to medically indigent and minority HIV infected women in Kansas City, MO, July 8, 2003.
35. "Managing the symptoms of hepatitis and its treatment" – Monthly educational meeting of the Patio Club (hepatitis support group that meets weekly at the Kansas City Free Health Clinic and is funded by a grant from the Centers for Disease Control), Kansas City, MO, June 2003
36. "Hepatitis A, B and C (Oh, and HIV too): Making it simple" – Monthly educational meeting of the Patio Club (hepatitis support group that meets weekly at the Kansas City Free Health Clinic and is funded by a grant from the Centers for Disease Control), Kansas City, MO, May 2003
37. "Hepatitis B treatment – what do we know?" - - Monthly educational meeting of the Patio Club (hepatitis support group that meets weekly at the Kansas City Free Health Clinic and is funded by a grant from the Centers for Disease Control), Kansas City, MO., April 2003
38. "Understanding HIV medicines" – Seminar provided to counselors for Camp Kendle, a nationwide attended camp for children with HIV infection, Lincoln, NE June 6, 2002
39. "HIV University for Women: Understanding Viral Replication" – Seminar provided to HIV infected women in Kansas City, May 23, 2002
40. "Improving relationships between patients and providers" - Kansas City Veteran's Affairs Hospital World AIDS Day patient education forum. Panelist, December 1, 2000.

Current Professional Organizations:

American Association of Colleges of Pharmacy
 American College of Clinical Pharmacy
 American Osteopathic Association
 American Pharmaceutical Association
 American Society for Microbiology
 American Society of Health-System Pharmacists

Association of Clinical Research Professionals
 Drug Information Association
 HIV Medicine Association - IDSA
 Infectious Diseases Society of America
 International Association of Physicians in AIDS Care
 Greater Kansas City Association of Health-System Pharmacists

Kansas City Infectious Diseases Society
 Mid-America College of Clinical Pharmacy
 Missouri Association of Health-System Pharmacists
 Missouri Association of Osteopathic Physicians

Phi Delta Chi Fraternity
 Society of Infectious Disease Pharmacists
 Heartland Association of Research Professionals

Non-refereed activities:

University of Buffalo – New York HIV Pharmacotherapy Network (an electronic reference and teaching platform for healthcare professionals about HIV. It provides evidence based answers to questions posed by members of the network regarding HIV disease process, epidemiology, transmission, plasma concentrations of antiretrovirals and optimization of all medications being used in persons infected with HIV). This training site is used by major chain pharmacies to teach their community pharmacists about HIV/AIDS and is updated annually. (<http://hiv.buffalo.edu/pharmacoeconomics.shtml>)

Positively Aware: (The Journal of Test Positive Aware Network)

This Medline referenced journal is a patient oriented magazine that has a bi-monthly publication run of over 75,000 copies plus an additional 10,000 individual subscriptions and 2,000 copies distributed at major HIV meetings in the United States and the Caribbean. Additionally, the online version of the magazine receives over 13,000 visits per month. (www.tpan.com)

- 2001 – 2006 Medical Advisory Board – review submitted articles for appropriateness and accuracy
- 2001 – ONG Contributing author and conference reviewer – provide occasional articles on timely topics, pharmacotherapy updates and summaries of conferences. These contributions can be found via Medline.
- 2001 – 2003 Contributing Editor, Annual Drug Guide – solicit contributors (from an international cohort of HIV-focused pharmacists), assemble documents and edit the final draft of the preeminent patient oriented drug guide in the world

Society of Infectious Disease Pharmacists Task Force on HIV-Focused Pharmacists (www.sidp.org); I realized the need for, initiated, received Board approval, and then solicited funding to develop a sub-group of this international organization that consists of those members that spend the majority of their time on HIV related issues. This group currently has 300+ of the US' leading HIV pharmacist clinician and researchers as members.

Community service and leisure activities

- 1986 – ONG Whole blood donor (every 8 weeks!)
- 1991 – ONG Life Member, American Legion (Veteran; Operation Desert Storm)
- 1998 – ONG Member, Friends of the Zoo (various zoos)
- 2000 – ONG Volunteer/Participant, AIDS Walks/Runs in greater Kansas City metropolitan area
- 2001 – ONG Member, Sacred Heart Catholic Church, Shawnee, Kansas
- 2004 – ONG Marathoner (5 and counting)
- 2004 – ONG Volunteer, DeSoto School District, multiple events, schools and involvement
- 2007 Physicians for Human Rights Summit: participated in education and advocacy meetings on Capitol Hill
- 2007 – 2010 W.A.T.C.H. DOGS, volunteer organization for fathers to get more involved in elementary schools.